Kura Oncology, Inc.

Quick facts

Phase 3 pipeline

• Cytarabine (Ara-C) · Oncology
  Cytarabine is a nucleoside analog that inhibits DNA synthesis by being incorporated into DNA, leading to chain termination and cell death, particularly affecting rapidly dividing cells.

Phase 1 pipeline

• Darlifarnib · Other

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Kura Oncology, Inc. portfolio CI brief
• Kura Oncology, Inc. pipeline updates RSS